Legal challenges, directives from elected and appointed leaders, and public funding reductions have intensified in recent months. How do companies remain compliant and committed to their missions? What changes will organizations have to consider to longstanding programs? What are the potential risks for future innovation? Attend this session to hear from leaders in the industry with expertise in leading organizations and companies committed to fostering a globally competitive industry that strengthens the biotechnology workforce and improves health outcomes for all.